HER2 is a target we should be considering in BTC’s starting in the first line. The overall response rates were 80% with 55% having a CR/PR. Interestingly it seems HER2 is much more prevalent in GBC compared to cholangio’s, at least in this study.
This antibody doublet is essentially the new SOC in met-urothelial cancer. The anti-PD1 and ADC combination is compelling in many ways and the survival outcomes compared to chemo were very significant. This combination is on NCCN, as well.
Interesting study where HPV+ head/neck cancer patients were assessed with a unique PET/CT with F-fluoromisonidazole, which assesses hypoxia in tissue. If, after two weeks of chemoradiation, the tumor became hypoxic, the patients were allowed to have chemotherapy alone while nonresponders went on to complete chemoradiation. At two years of follow-up, both arms were equivalent. There is more and more interest in how to safely de-escalate HPV+ head/neck cancer patients, but still, none have shown this can be done without compromising outcomes; this may be worth following to see if this works out.
Granted, this is a small study of 12 patients, it is nice to see an official report indicating safety regarding the use of CPI in the setting of advanced cutaneous SCC’s secondary to chronic immunosuppressive therapy after renal transplant. Patients were treated with steroids and rapamycin before/after the cemiplimab infusions, and no patients had rejection events.
Rare disease but nice to have an effective oral treatment option for PNH. Iptacopan, a first-in-class oral factor B inhibitor, has shown to improve Hb by >2g in the vast majority of patients in two studies discussed here.
Colorectal cancer screening by peripheral blood testing? This cell-free DNA assay had an 83% sensitivity and 90% specificity for advanced neoplasia. However, the issue is that this does not detect precancerous lesions well. Colonoscopy has its obvious advantages as it can both diagnose colorectal cancer as well as eradicate precancerous lesions.
For your stage II – III HR+, HER2-neg breast cancer patients. Adjuvant Ribociclib + AI showed a ~3% invasive DFS benefit vs. an AI alone (90 vs 87%). This is a 3-year treatment protocol as opposed to 5 years of an AI, which some patients may appreciate.
Phase 2 study showing that SABR for RCC is safe and feasible for those who refuse or are not candidates for surgery. The median age was 77, and this seems to be a safe, noninvasive alternative.
This combination had impressive results but led to a high rate of ventricular arrythmias (9%), hence the combination is not recommended. Another study with the combination and rituximab was also suspended, the etiology of the higher rate of Vent arrhythmias is not known. This combination in another lymphoid malignancies did not lead to that rate of toxicity.
A non-chemotherapy option for frail patients with advanced cHL. Brentuximab and nivolumab seems to be promising for those patients.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
